Note also that immu had an approval for their indication. So despite how some posts sound like leronlimab has already cured everything, the drug has not proven anything through a phase 3 trial except for HIV. Anything else is an assumption. We don't know Nash 700mg data, We've seen some highlights of mtnbc, but BTD shot down, COVID we speculate that 4 doses will be better than 2, not proven yet. HIV combo is the one we can verifiably say endpoint reached! All other indications a buying firm would need to fit the bill for all the trials and take on all the risk. Now if we had a successful HIV BLA filed and every other indication was just an extension of an already approved drug....we might have something there. Until then, unless all the data we haven't seen is stellar (not just the carefully selected highlights by mgmt in a PR), we aren't going to get top dollar in my humble opinion.

The varied indications does make leronlimab unique so I have no idea what a drug like that in it's infancy stages is worth, but not three figures yet.

One option mgmt could do, and I think ohm mentioned already (sorry if repeat). Present even a low-ball offer to shareholders, which might raise the price enough to sell some of the 200million for funding. Then we can negotiate from an even greater place of strength by getting the drug further developed.